Literature DB >> 8523100

Carbon-11-methionine PET evaluation of intracerebral hematoma: distinguishing neoplastic from non-neoplastic hematoma.

T Ogawa1, J Hatazawa, A Inugami, M Murakami, H Fujita, E Shimosegawa, K Noguchi, T Okudera, I Kanno, K Uemura.   

Abstract

UNLABELLED: We evaluated whether PET with L-methyl-11C-methionine (11C-methionine) was clinically useful in distinguishing neoplastic from non-neoplastic intracerebral hematoma.
METHODS: We examined eight patients with neoplastic (n = 4) or non-neoplastic (n = 4) intracerebral hematomas between 5 and 68 days after the bleeding episode using PET with 11C-methionine (Met-PET).
RESULTS: Carbon-11-methionine accumulated in the area surrounding the hematoma in both groups, except in one patient with an acute hypertensive hematoma. Between 22 and 45 days after the ictus, non-neoplastic hematomas showed increased 11C-methionine accumulation largely in accordance with the contrast-enhanced areas on CT or MR images; whereas between 14 and 68 days after bleeding, neoplastic hematomas showed increased 11C-methionine accumulation that extended beyond the contrast-enhanced areas on CT or MR images. The intensity of 11C-methionine accumulation in tumor tissue was greater than that in non-neoplastic hematomas.
CONCLUSION: Preliminary results suggest that Met-PET can distinguish neoplastic from non-neoplastic hematomas on the basis of differences in lesion extent compared with CT or MR findings.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8523100

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

Review 1.  11C-methionine PET/CT findings in benign brain disease.

Authors:  Reiko Nakajima; Ken Kimura; Koichiro Abe; Shuji Sakai
Journal:  Jpn J Radiol       Date:  2017-04-18       Impact factor: 2.374

Review 2.  Intracranial hemorrhage: the role of magnetic resonance imaging.

Authors:  Peter D Schellinger; Jochen B Fiebach
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

Review 3.  Exploring the nature of atheroma and cardiovascular inflammation in vivo using positron emission tomography (PET).

Authors:  J R Buscombe
Journal:  Br J Radiol       Date:  2015-09       Impact factor: 3.039

4.  123I-2-iodo-tyrosine, a new tumour imaging agent: human biodistribution, dosimetry and initial clinical evaluation in glioma patients.

Authors:  Marleen Keyaerts; Tony Lahoutte; Bart Neyns; Vicky Caveliers; Chris Vanhove; Hendrik Everaert; Ken Kersemans; Philippe R Franken; John Mertens; Axel Bossuyt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-20       Impact factor: 9.236

5.  Hybrid [18F]-F-DOPA PET/MRI Interpretation Criteria and Scores for Glioma Follow-up After Radiotherapy.

Authors:  Marc Bertaux; Arnaud Berenbaum; Anna-Luisa Di Stefano; Laura Rozenblum; Marine Soret; Sebastien Bergeret; Khé Hoang-Xuan; Laure-Eugenie Tainturier; Brian Sgard; Marie-Odile Habert; Jean-Yves Delattre; Caroline Dehais; Ahmed Idbaih; Nadya Pyatigorskaya; Aurelie Kas
Journal:  Clin Neuroradiol       Date:  2022-02-11       Impact factor: 3.156

Review 6.  11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas.

Authors:  Tarun Singhal; Tanjore K Narayanan; Viney Jain; Jogeshwar Mukherjee; Joseph Mantil
Journal:  Mol Imaging Biol       Date:  2007-10-24       Impact factor: 3.488

7.  11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma.

Authors:  Tetsuhiro Hatakeyama; Nobuyuki Kawai; Yoshihiro Nishiyama; Yuka Yamamoto; Yasuhiro Sasakawa; Tomotsugu Ichikawa; Takashi Tamiya
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-10       Impact factor: 9.236

8.  Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0.

Authors:  Ian Law; Nathalie L Albert; Javier Arbizu; Ronald Boellaard; Alexander Drzezga; Norbert Galldiks; Christian la Fougère; Karl-Josef Langen; Egesta Lopci; Val Lowe; Jonathan McConathy; Harald H Quick; Bernhard Sattler; David M Schuster; Jörg-Christian Tonn; Michael Weller
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-12-05       Impact factor: 9.236

9.  18F-FDOPA-PET in pseudotumoral brain lesions.

Authors:  Dimitri Renard; Laurent Collombier; Sabine Laurent-Chabalier; Thibault Mura; Anne Le Floch; Hassan El Fertit; Eric Thouvenot; Jean Sebastien Guillamo
Journal:  J Neurol       Date:  2020-10-21       Impact factor: 4.849

10.  Diagnostic Value of 11C-Methionine (MET) and 18F-Fluorothymidine (FLT) Positron Emission Tomography in Recurrent High-Grade Gliomas; Differentiation from Treatment-Induced Tissue Necrosis.

Authors:  Hajime Shishido; Nobuyuki Kawai; Keisuke Miyake; Yuka Yamamoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  Cancers (Basel)       Date:  2012-03-01       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.